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Fontan-Associated
Protein-Losing Enteropathy*
Gruschen R. Veldtman, MBCHB, Gary D. Webb, MDP rotein-losing enteropathy (PLE) has long beenrecognized as a potentially devastating com-plication of a Fontan procedure. Although not
very common, affecting perhaps 10% of Fontan pa-
tients, a consistently effective management strategy
has yet to be developed, and the 5-year mortality rate
is believed to be 50%. Accordingly, the paper in this
issue of the Journal by John et al. (1) is welcome in
that it addresses important questions of whether the
historical mortality data of PLE in Fontan patients still
holds true in the contemporary era and which treat-
ment strategies are most effective in managing such
patients. With the availability of new medical thera-
pies as well as interventional strategies, the reported
data represent a welcome extension to our knowledge
base. Our best data to this point came from the multi-
center study by Mertens et al. (2), suggesting a 50%
mortality at 5 years following the diagnosis of PLE.SEE PAGE 54John et al. (1) conducted a retrospective, cross-
sectional, hospital record–based study reviewing the
Mayo Clinic experience of 42 Fontan patients. These
patients (55% male) were diagnosed with PLE be-
tween 1992 and 2010. The diagnosis was based on a
combination of clinical symptoms, decreased serum
albumin levels, and elevated fecal alpha 1 antitrypsin
clearance. Public health records via Accurint also
were reviewed to assess mortality. The follow-up
period was 8  6 years (range 1 to 22 years).* Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From The Heart Institute, Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio. Both authors have reported that they have no re-
lationships relevant to the contents of this paper to disclose.Survival was 88% at 5 years; 11 patients in this
cohort died. The mean age at death was 32  7.7
years (range 22 to 47 years), and time from diag-
nosis to death was 7.5  5.4 years (range 1 to 18
years). The causes of death included sepsis (n ¼ 7),
complications after Fontan revision surgery (n ¼ 1),
and unknown (n ¼ 3). The authors identiﬁed the
following factors, assessed at the time of diagnosis,
as being associated with worse survival in this
cohort: Fontan pressure >15 mm Hg, New York Heart
Association functional class >II, higher pulmonary
vascular resistance, lower cardiac index, and lower
mixed venous oxygen saturation. Patients with PLE
who had Fontan pressures >15 mm Hg had worse sur-
vival at 5 years (83% vs. 95%) and 10 years (63% vs.
86%). PLE patients who had ejection fraction (EF)
of <55% had 5- and 10-year survival rates of 87% and
62%, whereas those PLE patients with EF of >55% had
5- and 10-year survival rates of 91% and 85%. Serum
creatinine levels were higher in the PLE patient cohort
that died (1.34  0.4 mg/dl vs. 0.84  0.33 mg/dl).
Serum albumin levels, alpha-1 antitrypsin levels, and
arrhythmia prevalence were not different between the
survivors and nonsurvivors.
Medical therapy alone was used in 15 of 42 pa-
tients. Of these, 7 (47%) improved, 5 (33%) did not
improve, and 3 (20%) died. Combined medical and
surgical/interventional treatment was used in the
remaining 27 patients. Of these, 10 (37%) improved, 9
(33%) did not improve, and 8 (30%) died. Surgical
treatment was used in 7 patients. Of these, the Fontan
was taken down in 2 patients (PLE got better in one
and was unchanged in the other); cardiac valve
replacement or repair was performed in 4 and cardiac
transplantation was performed in 1 patient, with
subsequent resolution of PLE.
This study has many strengths. It represents the
largest contemporary Fontan PLE series. It success-
fully demonstrated signiﬁcantly better outcomes
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64compared with the multicenter trial by Mertens et al.
(2) Survival was similar to that of another contem-
porary series, but this study was smaller and thus less
conclusive (3).
Surgical treatment was used more often in the
Mertens multicenter study (52 of 114 patients), and
62% died. On the other hand, 46% of their medically
treated patients died; therefore, the current results
represent a great apparent improvement. That said,
the current results were obtained from a relatively
shorter follow-up time (8 years vs. 18 years), as
compared with the multicenter series. Further
conﬁrmation of these promising outcomes is there-
fore awaited. One cannot assume that these results
are generalizable. The commitment and skills of in-
stitutions, teams, and individuals vary greatly and
will undoubtedly impact outcome.
This report does not present the denominator of
Fontan patients from whom this cohort was drawn.
Important questions remain, therefore, with respect
to whether the epidemiology and epigenetics of the
disease have changed over time. For example, have
better surgical planning and experience changed the
prevalence of PLE and has earlier management of
lower cardiac output states altered the disease state
and its natural history? Other sources of luminal
protein loss, such as plastic bronchitis, were not
speciﬁcally covered in this report. There is an
important and yet underrecognized role that defec-
tive lymphatic drainage plays, in addition to inﬂam-
mation at the level of the intestinal barrier, in
mediating abnormal luminal protein loss (4).
Results of medical therapy are difﬁcult to interpret
because crossover from the medical to the combined
medical/surgical/catheter-interventional group may
have occurred. The more recent availability of pul-
monary vasodilator therapies (5) and oral budesonide
(6–8) have substantially improved the armamen-
tarium available to treat this complex and multifac-
torial disease process, which may partly explain the
improved results.
Fontan hemodynamics at the commencement of
the protein-losing state appear to play an important
role in late outcomes. Higher venous pressures and
pulmonary vascular resistance, lower mixed venous
oxygen saturation, and EF <55% were associated in
univariate models with a worse late outcome. This is
not surprising given that a simple 2.5-mm H2O hy-
drostatic pressure increment augmented protein ﬂux
9-fold across the intestinal epithelial monolayer in an
experimental setting. Indeed, when a 2.5-mm H2O
pressure increment was combined with heparin sul-
fate loss in the same experimental epithelial cellmonolayer, a synergistic effect occurred that led to a
15.7-fold augmentation in albumin loss. These effects
could be further exaggerated in the presence of in-
ﬂammatory markers (tumor necrosis factor-alpha and
interferon-gamma) (8). It stands to reason, therefore,
that therapies primarily targeting inﬂammation and
Fontan hemodynamics are likely to meet with success.
In their discussion, John et al. (1) highlighted a role
for the detection and aggressive management of
obstructive sleep apnea in the treatment algorithm of
PLE. This is a potentially very important avenue for
further exploration. Very few data currently exist as
to how important this issue might be in this cohort.
There are, however, some signals that treatment of
sleep apnea may beneﬁt some Fontan patients (9).
Clearly, further work is needed to deﬁne the extent
and nature of this problem.
Sepsis was the dominant cause of mortality in pa-
tients with PLE in this series (7 of 11). Acquired im-
mune deﬁciency has previously been documented
(10). Both cellular and humoral immune compromise
may be present (11). This immune deﬁciency should
be a key focus of any therapeutic strategy. Looking
for and actively treating opportunistic infections,
particularly in the gut and respiratory tract may limit
inﬂammatory signaling known to promote albumin
loss via the intestinal epithelium. The mechanisms
of how immune deﬁciency develops needs further
exploration and may yield new therapeutic targets.
The researchers bring together their collective
experience with the management of PLE in present-
ing general treatment principles, as well as a useful
therapeutic algorithm. It should not be forgotten that
these patients may have profound nutritional deﬁ-
cits, not dissimilar to kwashiorkor and consisting not
only of hypoproteinemia (including clotting factors)
but also involving trace elements, fat soluble vita-
mins, iron, magnesium, and calcium, to name a few.
These deﬁciencies in turn may adversely affect in-
testinal barrier function through altering transcellular
and paracellular transport mechanisms and therefore
should be considered an important component of
supportive therapy.
It has long been recognized that intestinal function
may be altered under certain pathological states. For
instance, the colon plays a greater absorptive role in
the presence of small-bowel dysfunction and has
been demonstrated to “rescue” malabsorbed carbo-
hydrate. This phenomenon may be used in the setting
of PLE by prolonging gut transfer time, and this was
recently demonstrated to be useful (12).
In conclusion, this paper summarized the con-
temporary outcomes following a diagnosis of PLE
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65in Fontan patients and discussed potential thera-
peutic approaches. The data, although reassuring that
progress has been made, clearly call for further ex-
perimental and observational endeavors to improve
management of this chronic, debilitating, and fre-
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